Starboard Value LP underperformed peers in 2024, a year in which Jeff Smith’s activist firm was frustrated with large ...

(Bloomberg) -- Pfizer Inc. company officials threatened legal action against two former top executives who had been working ...

Activist investor Starboard Value has launched a broadside against Pfizer's leadership under chief executive Albert Bourla, claiming at least $20 billion in value – and possibly as much as $60 ...

Two former Pfizer executives drawn into a campaign by activist investor Starboard Value to shake up the company have withdrawn their support for the plan. Pfizer's ex-chair and chief executive Ian ...

Pfizer on Monday named the former head of the U.S. health regulator's drug evaluation unit, Patrizia Cavazzoni, as its chief ...

Jeffrey Smith’s Starboard Value disclosed in an SEC filing its holdings as of December 31, 2024. The fund’s new buys during the fourth quarter ...

The all-or-nothing strategy has landed the ‘pride of the pharmaceutical industry' in a situation that deteriorated rapidly.

Pfizer got a reprieve in late January when Starboard did not nominate its own slate of directors to the company’s board, but the activist could still agitate for changes in 2026. Among Pfizer ...

Pfizer appears to have dodged a proxy battle with activist investor Starboard Value, which has a roughly $1 billion stake in the pharmaceutical giant, for now. The deadline passed for nominating ...

That Pfizer’s turnaround is already well underway is reflected by the fact that activist investor Starboard Value, led by Jeffrey Smith, wisely chose not to nominate any dissident directors to ...